Alto Neuroscience (NYSE:ANRO) Price Target Raised to $60.00

Alto Neuroscience (NYSE:ANRO) had its price target raised by HC Wainwright from $55.00 to $60.00 in a research report report published on Monday, Marketbeat Ratings reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Alto Neuroscience’s Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.69) EPS, FY2026 earnings at ($2.82) EPS, Q1 2027 earnings at ($0.76) EPS, Q2 2027 earnings at ($0.79) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.80) EPS, FY2027 earnings at ($3.17) EPS, FY2028 earnings at ($4.00) EPS, FY2029 earnings at ($4.01) EPS and FY2030 earnings at ($3.51) EPS.

ANRO has been the topic of several other reports. Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Zacks Research upgraded Alto Neuroscience from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Wedbush increased their target price on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Finally, BTIG Research lifted their price target on Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.88.

Alto Neuroscience Trading Down 4.2%

NYSE ANRO opened at $23.38 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 14.85 and a quick ratio of 14.85. The company’s 50-day simple moving average is $29.86 and its two-hundred day simple moving average is $26.33. Alto Neuroscience has a one year low of $9.73 and a one year high of $37.48.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.08. Analysts forecast that Alto Neuroscience will post -2.69 earnings per share for the current year.

Insider Buying and Selling

In other Alto Neuroscience news, CFO Nicholas Smith sold 110,830 shares of the stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $26.58, for a total transaction of $2,945,861.40. Following the completion of the sale, the chief financial officer directly owned 24,060 shares of the company’s stock, valued at approximately $639,514.80. This represents a 82.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.25% of the company’s stock.

Institutional Trading of Alto Neuroscience

Institutional investors have recently modified their holdings of the company. Commodore Capital LP grew its position in shares of Alto Neuroscience by 49.4% in the 1st quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock worth $61,217,000 after buying an additional 900,000 shares during the last quarter. Perceptive Advisors LLC lifted its position in Alto Neuroscience by 12.6% during the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after acquiring an additional 225,500 shares during the last quarter. Spruce Street Capital LP lifted its position in Alto Neuroscience by 494.7% during the first quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after acquiring an additional 1,102,366 shares during the last quarter. Affinity Asset Advisors LLC acquired a new stake in Alto Neuroscience in the first quarter valued at approximately $11,240,000. Finally, Jennison Associates LLC purchased a new position in Alto Neuroscience in the first quarter worth $8,687,000.

Key Alto Neuroscience News

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and raised its price target to $60, well above recent trading levels. The analyst also improved EPS forecasts for 2027 and 2028, including FY2027 losses of $3.17 per share versus a prior estimate of $3.87 and FY2028 losses of $4.00 versus $4.39. These revisions suggest expectations for improved financial performance over the medium term. Alto Neuroscience Stock Gets Price Target Boost from HC Wainwright
• Neutral Sentiment: The analyst expects Alto Neuroscience to remain unprofitable, forecasting EPS losses of $2.82 for FY2026 and $3.17 for FY2027. The estimates imply continued cash burn, although the company’s strong liquidity and low debt may provide flexibility to fund development.
• Negative Sentiment: HC Wainwright slightly reduced its FY2026 forecast to a $2.82-per-share loss from $2.80 and lowered estimates for the third quarter of 2026 and fourth quarter of 2026. More notably, longer-term loss estimates worsened for FY2029, to $4.01 from $3.25, and FY2030, to $3.51 from $1.29. Those revisions raise concerns about the pace of the company’s path toward profitability.

About Alto Neuroscience

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and central nervous system disorders. The company combines neuroscience research, clinical data and biomarker-based approaches to identify patients who may be more likely to respond to specific treatments.

Alto Neuroscience’s investigational pipeline includes therapies intended to address conditions such as major depressive disorder, bipolar depression, schizophrenia and associated cognitive impairment.